152 related articles for article (PubMed ID: 34185342)
1. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement.
Oubari S; Naser E; Papathanasiou M; Luedike P; Hagenacker T; Thimm A; Rischpler C; Kessler L; Kimmich C; Hegenbart U; Schönland S; Rassaf T; Reinhardt HC; Jöckel KH; Dürig J; Dührsen U; Carpinteiro A
Eur J Haematol; 2021 Oct; 107(4):449-457. PubMed ID: 34185342
[TBL] [Abstract][Full Text] [Related]
2. Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis.
Hwa YL; Gertz MA; Kumar SK; Lacy MQ; Buadi FK; Dingli D; Kapoor P; Zeldenrust SR; Leung N; Hayman SR; Gonsalves WI; Kourelis TV; Warsame R; Go RS; Muchtar E; Hobbs MA; Fonder AL; Russell S; Kyle RA; Rajkumar SV; Dispenzieri A
Leukemia; 2019 May; 33(5):1268-1272. PubMed ID: 30737485
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019.
Hester LL; Gifkins DM; M Bellew K; Vermeulen J; Schecter JM; Strony J; Dishy V; Weiss BM
Eur J Haematol; 2021 Oct; 107(4):428-435. PubMed ID: 34137077
[TBL] [Abstract][Full Text] [Related]
4. Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016.
Rutten KHG; Raymakers RAP; Hazenberg BPC; Nienhuis HLA; Vellenga E; Minnema MC
Amyloid; 2018 Dec; 25(4):227-233. PubMed ID: 30513220
[TBL] [Abstract][Full Text] [Related]
5. Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy - A Single-Center Cohort Study of 227 Patients.
Feng J; Zhang C; Shen K; Sun J; Fang Q; Zhang L; Cao X; Zhou D; Li J; Tian Z
Circ J; 2019 Mar; 83(4):775-782. PubMed ID: 30773521
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and safety of daratumumab in the treatment of advanced light chain amyloidosis].
Shen KN; Miao HL; Gao YJ; Cao XX; Zhou DB; Su W; Li J
Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):31-34. PubMed ID: 35231990
[No Abstract] [Full Text] [Related]
7. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis.
Salinaro F; Meier-Ewert HK; Miller EJ; Pandey S; Sanchorawala V; Berk JL; Seldin DC; Ruberg FL
Eur Heart J Cardiovasc Imaging; 2017 Sep; 18(9):1057-1064. PubMed ID: 27965280
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
[TBL] [Abstract][Full Text] [Related]
9. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study.
Shen KN; Zhang CL; Tian Z; Feng J; Wang YN; Sun J; Zhang L; Cao XX; Zhou DB; Li J
Amyloid; 2019 Jun; 26(2):66-73. PubMed ID: 31074308
[No Abstract] [Full Text] [Related]
11. Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis.
Yogo T; Okazuka K; Nashimoto J; Uto Y; Sato K; Miyazaki K; Ogura M; Yoshiki Y; Abe Y; Tsukada N; Ishida T; Suzuki K
Int J Hematol; 2019 Oct; 110(4):431-437. PubMed ID: 31236823
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.
Bézard M; Oghina S; Vitiello D; Kharoubi M; Kordeli E; Galat A; Zaroui A; Guendouz S; Gilles F; Shourick J; Hamon D; Audard V; Teiger E; Poullot E; Molinier-Frenkel V; Lemonnier F; Agbulut O; Le Bras F; Damy T
PLoS One; 2021; 16(9):e0257189. PubMed ID: 34525116
[TBL] [Abstract][Full Text] [Related]
13. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T; Gatt M; Lavie N; Vaxman I; Tadmor T; Rouvio O; Zektser M; Horowitz N; Magen H; Ballan M; Suru C; Luttwak E; Levi S; Ziv-Baran T; Avivi I; Cohen YC
Eur J Haematol; 2021 Feb; 106(2):184-195. PubMed ID: 33090552
[TBL] [Abstract][Full Text] [Related]
15. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
16. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
Wong SW; Hegenbart U; Palladini G; Shah GL; Landau HJ; Warner M; Toskic D; Jaccard A; Hansen T; Bladé J; Cibeira MT; Kastritis E; Dispenzieri A; Wechalekar A; Varga C; Schönland SO; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e493-e499. PubMed ID: 30104177
[TBL] [Abstract][Full Text] [Related]
17. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.
Palladini G; Milani P; Foli A; Basset M; Russo F; Perlini S; Merlini G
Blood; 2018 Feb; 131(5):525-532. PubMed ID: 29101236
[TBL] [Abstract][Full Text] [Related]
18. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
[TBL] [Abstract][Full Text] [Related]
19. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
[TBL] [Abstract][Full Text] [Related]
20. A real-world study on diagnosis and prognosis of light-chain cardiac amyloidosis in Southern China.
Wu Z; Li M; Ilyas T; Li W; Zeng M; Li F; Liu Y; Chen M; Chen Y; Zhu Q; Qi N; Liu Q; Tang J
BMC Cardiovasc Disord; 2021 Sep; 21(1):452. PubMed ID: 34537003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]